US Stock MarketDetailed Quotes
BRTX Biorestorative Therapies
- 1.270
- -0.070-5.22%
Close Apr 24 16:00 ET
- 1.210
- -0.060-4.72%
Pre 08:28 ET
8.60MMarket Cap-371P/E (TTM)
1.360High1.250Low84.35KVolume1.350Open1.340Pre Close106.89KTurnover1.54%Turnover RatioLossP/E (Static)6.77MShares7.13052wk High0.75P/B6.98MFloat Cap1.20052wk Low--Dividend TTM5.50MShs Float8.900Historical High--Div YieldTTM8.21%Amplitude1.200Historical Low1.267Avg Price1Lot Size
Biorestorative Therapies Stock Forum
Sign in to post a comment
Therapy Company Secures FDA Clearance For Amended Lower Back Pain Treatment Clinical Study
Breakthrough in Back Pain Treatment: BioRestorative Therapies' Major FDA Milestone.
In an era where chronic back pain has emerged as a prevalent affliction affecting millions worldwide, a glimmer of hope shines through the efforts of BioRestorative Therapies, Inc. (BRTX). The company recently announced a significant leap forward in its quest to offer a revolutionary treatment for lower back pain caused by d...
In an era where chronic back pain has emerged as a prevalent affliction affecting millions worldwide, a glimmer of hope shines through the efforts of BioRestorative Therapies, Inc. (BRTX). The company recently announced a significant leap forward in its quest to offer a revolutionary treatment for lower back pain caused by d...
$Biorestorative Therapies(BRTX.US$ BioRestorative Therapies (BRTX) said Tuesday that the US Food and Drug Administration has cleared an amendment to the protocol of the current phase 2 trial of its cell therapy candidate, BRTX-100, to treat chronic lumbar disc disease.
1
$Biorestorative Therapies(BRTX.US$ why Izzit dropping?
5
$Biorestorative Therapies(BRTX.US$ hugs opportunity 🏆🔥🔥🏆💯
$Biorestorative Therapies(BRTX.US$
NEWS
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
BioRestorative Therapies announces FDA clearance of Phase 2 BRTX-100 clinical study protocol amendment, replacing saline injections with sham injections in the control group. The amendment aims to enhance safety and prevent transient clinical outcomes, maintaining the 2024 enrollment completion target.
NEWS
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
BioRestorative Therapies announces FDA clearance of Phase 2 BRTX-100 clinical study protocol amendment, replacing saline injections with sham injections in the control group. The amendment aims to enhance safety and prevent transient clinical outcomes, maintaining the 2024 enrollment completion target.
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Ray P : pullback for the pop to2 or 3 dollars then back down